Abstract 98P
Background
Lung cancer represents the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for ∼85% of total cases. Although immunotherapy using immune checkpoint inhibitors (ICI) has shown promising results, only a subset of patients benefits from it and there is an urgent need for reliable predictive response biomarkers. Furthermore, traditional tissue biopsies are limited in size and provide a biased representation of the tumour. Therefore, we aimed to explore the possibility to obtain predictive biomarkers of response to ICI in a non-invasive way using liquid biopsy (LB).
Methods
To counter this, we analysed samples from 25 patients from advanced NSCLC treated with pembrolizumab at first line. Blood and tissue samples were collected at baseline to obtain cell-free DNA (cfDNA) and genomic DNA from plasma and PBMCs respectively, and tumour DNA from FFPE primary tumour. All samples underwent a target NGS panel to call somatic mutations in circulating tumour DNA (ctDNA) and primary tumour, evaluating their potential as predictive biomarkers.
Results
Through the integration of three different bioinformatic approaches for variant calling and ROC curve analysis, we identified mutations in key cancer-related genes associated with a 3-month radiological response. We also assessed a promising mutational signature in ctDNA comprising 10 genes with a high ability to predict response to ICI (AUC = 0.98). Although we explored copy number alterations and tumour mutational burden in LB, results did not yield statistical significance, suggesting that assessment of point mutations in particular genes and the proposed signature hold higher potential as biomarkers. Moreover, we compared ctDNA analysis with tissue biopsies, revealing a high concordance between ctDNA and primary tumour, enhancing the reliability of ctDNA analysis as a good alternative for tumour assessment.
Conclusions
These findings highlight the value of ctDNA analysis as a non-invasive predictive biomarker for ICI response and its correlation with mutations found in primary tumours. We also proposed a mutational signature to predict response at baseline for advanced NSCLC ICI treated patients, which could be readily implemented in the clinical management of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Translational Molecular Oncology Unit. IIS Galicia Sur.
Funding
Vigo Contra el Cáncer; GAIN; Xunta de Galicia (ED481A-2020/214); Miguel Servet program (CP20/00188).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract